tamoxifen Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
2561 10540-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tamoxifen
  • tamoxifen citrate
  • tamoxifene
  • tamoxifene citrate
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
  • Molecular weight: 371.52
  • Formula: C26H29NO
  • CLOGP: 6.82
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.56
  • ROTB: 8

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1977 FDA

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1419.14 32.57 375 3043 28661 4606913
Metastases to bone 1376.26 32.57 260 3158 4086 4631488
Metastases to liver 764.42 32.57 167 3251 5475 4630099
Breast cancer 697.68 32.57 174 3244 10237 4625337
Breast cancer metastatic 666.27 32.57 129 3289 2275 4633299
Metastases to lung 484.06 32.57 106 3312 3481 4632093
Disease progression 477.16 32.57 178 3240 40833 4594741
Death 418.90 32.57 266 3152 197897 4437677
Metastases to lymph nodes 407.13 32.57 83 3335 1910 4633664
Breast cancer recurrent 377.63 32.57 68 3350 783 4634791
Metastasis 360.79 32.57 76 3342 2060 4633514
Uterine polyp 299.63 32.57 50 3368 352 4635222
Hot flush 276.22 32.57 84 3334 10191 4625383
Acute myeloid leukaemia 261.55 32.57 74 3344 6971 4628603
Neoplasm progression 257.81 32.57 77 3341 8778 4626796
Arthralgia 198.87 32.57 121 3297 81873 4553701
Endometrial hyperplasia 197.10 32.57 33 3385 237 4635337
Pseudocirrhosis 180.01 32.57 28 3390 117 4635457
Pulmonary embolism 171.24 32.57 82 3336 34344 4601230
Fatigue 169.68 32.57 137 3281 145429 4490145
Second primary malignancy 162.67 32.57 42 3376 2786 4632788
Metastases to spine 154.89 32.57 32 3386 782 4634792
Endometrial cancer 154.71 32.57 31 3387 647 4634927
Neuropathy peripheral 147.63 32.57 66 3352 23603 4611971
Endometrial hypertrophy 146.37 32.57 23 3395 104 4635470
Breast cancer female 142.80 32.57 33 3385 1372 4634202
Metastases to skin 139.99 32.57 26 3392 357 4635217
Carbohydrate antigen 15-3 increased 128.52 32.57 21 3397 127 4635447
Tumour marker increased 121.91 32.57 27 3391 924 4634650
Pleural effusion 120.82 32.57 58 3360 24340 4611234
Dyspnoea 111.57 32.57 106 3312 138879 4496695
Metastases to central nervous system 107.57 32.57 33 3385 4091 4631483
Insomnia 107.17 32.57 66 3352 45279 4590295
Invasive ductal breast carcinoma 104.60 32.57 24 3394 965 4634609
Asthenia 103.98 32.57 83 3335 86080 4549494
Deep vein thrombosis 103.63 32.57 53 3365 25441 4610133
Hysterectomy 101.18 32.57 26 3392 1688 4633886
Hysteroscopy 99.39 32.57 14 3404 23 4635551
Diarrhoea 99.13 32.57 103 3315 150082 4485492
Bone pain 98.27 32.57 42 3376 13444 4622130
Disease recurrence 95.86 32.57 35 3383 7406 4628168
Endometrial atrophy 94.36 32.57 14 3404 39 4635535
Metastases to the mediastinum 92.32 32.57 16 3402 144 4635430
Maculopathy 91.97 32.57 21 3397 826 4634748
Nausea 91.72 32.57 107 3311 177226 4458348
Uterine cancer 91.33 32.57 21 3397 852 4634722
Hepatic steatosis 90.39 32.57 32 3386 6196 4629378
Vaginal haemorrhage 87.97 32.57 30 3388 5199 4630375
Vomiting 87.83 32.57 87 3331 119612 4515962
Pulmonary mass 87.15 32.57 27 3391 3456 4632118
Depression 86.93 32.57 59 3359 47674 4587900
Anaemia 86.39 32.57 69 3349 71491 4564083
Oestrogen receptor positive breast cancer 85.04 32.57 13 3405 47 4635527
Osteonecrosis of jaw 84.80 32.57 38 3380 13609 4621965
Portal hypertension 82.10 32.57 21 3397 1338 4634236
Hepatic lesion 80.26 32.57 20 3398 1146 4634428
Alopecia 79.62 32.57 46 3372 28034 4607540
Visual acuity reduced 78.92 32.57 33 3385 9997 4625577
Disturbance in attention 77.22 32.57 33 3385 10548 4625026
Ovarian cancer 76.61 32.57 20 3398 1381 4634193
Pain 74.61 32.57 71 3347 92799 4542775
Recurrent cancer 72.99 32.57 17 3401 730 4634844
Sarcoma uterus 71.69 32.57 11 3407 41 4635533
Pain in extremity 71.68 32.57 59 3359 63680 4571894
Drug intolerance 70.76 32.57 39 3379 21707 4613867
Neutropenia 70.43 32.57 52 3366 47898 4587676
Myalgia 69.52 32.57 49 3369 41999 4593575
Uterine leiomyoma 69.33 32.57 19 3399 1579 4633995
Tinnitus 68.34 32.57 29 3389 9104 4626470
Endocervical curettage 68.04 32.57 9 3409 6 4635568
Hepatic cirrhosis 67.59 32.57 25 3393 5477 4630097
Weight increased 66.03 32.57 45 3373 36536 4599038
Arthropathy 63.94 32.57 29 3389 10669 4624905
Breast mass 62.51 32.57 17 3401 1373 4634201
Menopausal symptoms 60.49 32.57 13 3405 385 4635189
Headache 60.00 32.57 72 3346 122301 4513273
Onycholysis 59.39 32.57 13 3405 420 4635154
Uterine dilation and curettage 59.21 32.57 12 3406 265 4635309
Lymphoedema 59.04 32.57 17 3401 1691 4633883
Paraesthesia 58.18 32.57 41 3377 35092 4600482
Myelodysplastic syndrome 58.13 32.57 24 3394 7034 4628540
Metastases to chest wall 57.99 32.57 10 3408 87 4635487
Deafness 57.86 32.57 22 3396 5197 4630377
Cardiotoxicity 57.71 32.57 19 3399 2951 4632623
Endometriosis 57.64 32.57 14 3404 720 4634854
Bone lesion 55.42 32.57 15 3403 1189 4634385
Acute promyelocytic leukaemia 52.89 32.57 12 3406 458 4635116
Palmar-plantar erythrodysaesthesia syndrome 52.41 32.57 24 3394 9017 4626557
Ovarian cyst 51.75 32.57 16 3402 2031 4633543
Decreased appetite 50.76 32.57 46 3372 56351 4579223
Nasal disorder 50.38 32.57 12 3406 568 4635006
Sleep disorder 50.34 32.57 25 3393 11238 4624336
Metastases to peritoneum 50.21 32.57 13 3405 868 4634706
Gait disturbance 49.89 32.57 38 3380 36602 4598972
Constipation 49.38 32.57 40 3378 42114 4593460
Drug resistance 48.43 32.57 22 3396 8114 4627460
Vulvovaginal dryness 47.74 32.57 11 3407 450 4635124
Skin hypopigmentation 47.67 32.57 10 3408 263 4635311
Pyrexia 47.55 32.57 60 3358 107084 4528490
Leiomyoma 47.33 32.57 9 3409 141 4635433
Fibrous histiocytoma 46.80 32.57 9 3409 150 4635424
Postmenopausal haemorrhage 46.63 32.57 11 3407 499 4635075
Tonsillar disorder 46.14 32.57 10 3408 308 4635266
Cognitive disorder 46.06 32.57 23 3395 10458 4625116
Electrocardiogram QT prolonged 45.83 32.57 26 3392 15269 4620305
Aspartate aminotransferase increased 45.73 32.57 31 3387 24907 4610667
Hypertriglyceridaemia 45.50 32.57 15 3403 2338 4633236
Cervical polyp 45.48 32.57 8 3410 79 4635495
RET gene mutation 45.35 32.57 6 3412 4 4635570
Hyperhidrosis 45.13 32.57 33 3385 29884 4605690
Back pain 44.99 32.57 41 3377 50558 4585016
Alanine aminotransferase increased 44.39 32.57 32 3386 28341 4607233
Vitreous detachment 44.13 32.57 11 3407 630 4634944
Pleural disorder 44.05 32.57 9 3409 207 4635367
Metastatic neoplasm 43.78 32.57 13 3405 1439 4634135
Dural arteriovenous fistula 43.31 32.57 7 3411 39 4635535
Cough 41.70 32.57 41 3377 55546 4580028
Mass 41.38 32.57 15 3403 3100 4632474
Oedema peripheral 41.25 32.57 36 3382 41936 4593638
Superior sagittal sinus thrombosis 40.58 32.57 9 3409 309 4635265
Weight decreased 40.54 32.57 40 3378 54424 4581150
Metastases to pleura 40.53 32.57 9 3409 311 4635263
Vein disorder 40.46 32.57 11 3407 886 4634688
Adenocarcinoma 40.44 32.57 11 3407 888 4634686
Osteoporosis 40.04 32.57 18 3400 6477 4629097
Tumour invasion 39.58 32.57 8 3410 174 4635400
General physical health deterioration 39.50 32.57 30 3388 28748 4606826
Left ventricular dysfunction 39.41 32.57 14 3404 2731 4632843
Ejection fraction decreased 39.31 32.57 17 3401 5579 4629995
Neuralgia 39.29 32.57 16 3402 4524 4631050
Blood creatinine decreased 39.27 32.57 11 3407 990 4634584
Metastases to ovary 38.94 32.57 7 3411 79 4635495
Breast cancer in situ 38.85 32.57 9 3409 377 4635197
Corneal disorder 38.70 32.57 10 3408 662 4634912
Mucosal inflammation 38.68 32.57 21 3397 11322 4624252
Lymphangioleiomyomatosis 38.19 32.57 6 3412 27 4635547
Polyneuropathy 38.17 32.57 15 3403 3866 4631708
Musculoskeletal chest pain 38.15 32.57 15 3403 3873 4631701
Lymphadenopathy mediastinal 37.65 32.57 10 3408 737 4634837
Metastases to meninges 37.61 32.57 10 3408 740 4634834
Lymphadenopathy 37.56 32.57 20 3398 10372 4625202
Metastases to uterus 37.51 32.57 6 3412 31 4635543
Porphyria non-acute 36.74 32.57 8 3410 252 4635322
Dizziness 36.67 32.57 51 3367 99820 4535754
Blood pressure diastolic increased 36.67 32.57 10 3408 815 4634759
Aplastic anaemia 36.60 32.57 12 3406 1839 4633735
Injection site hypersensitivity 36.22 32.57 9 3409 509 4635065
Haemorrhage 35.86 32.57 27 3391 25535 4610039
Hepatic failure 35.78 32.57 21 3397 13128 4622446
Abdominal pain 35.53 32.57 39 3379 59985 4575589
Anxiety 35.23 32.57 35 3383 47976 4587598
Oestradiol abnormal 35.20 32.57 5 3413 9 4635565
Joint stiffness 34.97 32.57 16 3402 5995 4629579
Enlarged clitoris 34.51 32.57 6 3412 55 4635519
Papilloedema 34.35 32.57 11 3407 1564 4634010
Blood lactate dehydrogenase increased 34.33 32.57 17 3401 7586 4627988
Oophorectomy 34.06 32.57 7 3411 166 4635408
Trigger finger 33.84 32.57 9 3409 667 4634907
Musculoskeletal pain 33.73 32.57 22 3396 16566 4619008
Thrombocytopenia 33.60 32.57 34 3384 47639 4587935
Blood uric acid decreased 33.26 32.57 7 3411 187 4635387
Cerebral venous thrombosis 33.21 32.57 9 3409 716 4634858
Malignant pleural effusion 33.02 32.57 9 3409 732 4634842
Febrile neutropenia 32.99 32.57 26 3392 26286 4609288
PIK3CA-activated mutation 32.94 32.57 5 3413 17 4635557
Peritoneal disorder 32.70 32.57 7 3411 203 4635371
Metastases to soft tissue 32.59 32.57 6 3412 78 4635496

Pharmacologic Action:

SourceCodeDescription
ATC L02BA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-estrogens
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D050071 Bone Density Conservation Agents
MeSH PA D004965 Estrogen Antagonists
MeSH PA D020847 Estrogen Receptor Modulators
MeSH PA D006727 Hormone Antagonists
MeSH PA D020845 Selective Estrogen Receptor Modulators
CHEBI has role CHEBI:50837 estrogen antagonist
CHEBI has role CHEBI:50739 estrogen receptor modulator
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:50792 estrogen receptor antagonist
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000175826 Estrogen Agonist/Antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infiltrating duct carcinoma of breast indication 408643008 DOID:3008
Carcinoma of female breast indication 447782002
Prevention of Breast Carcinoma indication
Endometrial carcinoma off-label use 254878006 DOID:2871
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercalcemia contraindication 66931009 DOID:12678
Leukopenia contraindication 84828003 DOID:615
Bilateral cataracts contraindication 95722004
Deep venous thrombosis contraindication 128053003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor MODULATOR Ki 7.51 CHEMBL CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.36 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.15 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.37 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.33 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.40 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.14 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 5.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.84 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.16 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.86 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.62 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.79 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.44 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.03 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.56 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.20 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.73 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.84 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.86 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.68 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 5.41 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.61 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.20 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.33 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.45 DRUG MATRIX
Substance-P receptor GPCR Ki 5.07 DRUG MATRIX
Tyrosine-protein kinase Lck Kinase IC50 5.10 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.92 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.53 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 6.04 DRUG MATRIX
Substance-K receptor GPCR Ki 5.91 DRUG MATRIX
B2 bradykinin receptor GPCR Ki 4.92 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.53 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 4.60 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.76 DRUG MATRIX
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Enzyme IC50 4.51 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.50 WOMBAT-PK
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor Ki 7.46 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.06 WOMBAT-PK
Estrogen-related receptor gamma Nuclear hormone receptor Ki 7.10 WOMBAT-PK
G-protein coupled estrogen receptor 1 GPCR IC50 7.50 WOMBAT-PK
Estrogen receptor beta Nuclear hormone receptor IC50 5.91 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 5.66 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 7 WOMBAT-PK
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 8.30 WOMBAT-PK
Prostaglandin G/H synthase 2 Enzyme IC50 4.46 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 5.98 CHEMBL
Emopamil-binding protein-like Unclassified Ki 8.55 CHEMBL
Steroid hormone receptor ERR1 Nuclear hormone receptor IC50 6.70 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.80 CHEMBL
Anti-estrogen binding site (AEBS) Enzyme Kd 9 CHEMBL
Progesterone receptor Nuclear hormone receptor IC50 6.89 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.00 DRUG MATRIX
Androgen receptor Transcription factor Ki 4.82 DRUG MATRIX
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 4.81 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.42 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.59 DRUG MATRIX
Transcriptional activator protein luxR Unclassified IC50 4.40 CHEMBL
C-8 sterol isomerase Enzyme Ki 5.82 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.92 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 4.66 CHEMBL

External reference:

IDSource
4019939 VUID
N0000148024 NUI
C0039286 UMLSCUI
D00966 KEGG_DRUG
094ZI81Y45 UNII
3299 INN_ID
54965-24-1 SECONDARY_CAS_RN
75959001 SNOMEDCT_US
4019939 VANDF
2281 MMSL
10324 RXNORM
373345002 SNOMEDCT_US
d00381 MMSL
004826 NDDF
CHEMBL83 ChEMBL_ID
CHEMBL786 ChEMBL_ID
DB00675 DRUGBANK_ID
CHEBI:41774 CHEBI
D013629 MESH_DESCRIPTOR_UI
2733526 PUBCHEM_CID
1016 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0144 TABLET 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0274 TABLET 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2472 TABLET 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2473 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0485 TABLET 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0942 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-446 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-447 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-3004 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-4287 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-909 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-910 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63187-976 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63739-269 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 65084-269 TABLET, FILM COATED 10 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68071-5005 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68382-826 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68382-827 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1881 TABLET 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1184 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 70771-1185 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 71335-0237 TABLET, FILM COATED 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 71335-0893 TABLET 20 mg ORAL ANDA 13 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 71335-1424 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
Soltamox HUMAN PRESCRIPTION DRUG LABEL 1 89141-123 LIQUID 20 mg ORAL NDA 21 sections